Thanks to the development of advanced therapies, the goal of remission is within reach for more and more patients with inflammatory rheumatic diseases [1]. In the following podcast, Prof. Stephan Krähenbühl explains the role of Janus kinase (JAK) inhibitors as a targeted oral treatment and what needs to be considered when using them. Have fun listening!
The development of JAK inhibitors, with their broad spectrum of activity on various cytokines involved in the pathogenesis of inflammatory rheumatic diseases, has opened new perspectives on the management of rheumatoid arthritis (RA), ankylosing spondyloarthritis (AS), and psoriatic arthritis (PsA) [1]. Learn more about the following topics in the podcast with Prof. Stephan Krähenbühl, University Hospital Basel:
- What is the story behind the development of JAK inhibitors?
- What are the differences between the various JAK inhibitors?
- What is there to consider in practical application?
- What are the realistic therapeutic targets with JAK inhibitors today?
References:
1 Tanaka Y et al. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol, 2022. 18(3): p. 133-145.
The references can be requested by professionals at medinfo.ch@abbvie.com.
With the financial support of AbbVie AG, Alte Steinhauserstrasse 14, 6330 Cham.
Dr. sc. nat. Jennifer Keim
CH-RNQR-230003_01/2023
Post online since 27.02.2023
